Biotheus Inc.
19
3
10
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.4% vs industry average
11%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Role: lead
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Role: lead
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Role: collaborator
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Role: lead
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
Role: lead
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
Role: lead
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Role: lead
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
Role: lead
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
Role: lead
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Role: lead
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
Role: lead
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Role: lead
PM8002 in the Treatment of Patients With Advanced Solid Tumors
Role: lead
A Study of PM1015 in Patients With Advanced Solid Tumors
Role: lead
A Study of PM1022 in Patients With Advanced Tumors
Role: lead
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
Role: lead
Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
Role: lead
A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours
Role: lead
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
Role: lead
All 19 trials loaded